LYNPARZA® (Olaparib)

The FDA on May 31, 2023, approved LYNPARZA® (Olaparib) along with Abiraterone and Prednisone (or Prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic Castration-Resistant Prostate Cancer (mCRPC), as determined by an FDA-approved companion diagnostic test. LYNPARZA® is a product of AstraZeneca Pharmaceuticals LP.